Literature DB >> 19413596

Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.

Xin-Yan Zhao1, Xin Zeng, Xin-Min Li, Tai-Ling Wang, Bao-En Wang.   

Abstract

1. Pirfenidone (PFD; 5-methyl-1-phenyl-2(1H)-pyridone) is an effective and novel agent with antifibrotic and anti-inflammatory properties. In the present study, we investigated the antifibrotic effects of PFD on experimental liver fibrosis models in rodents and the possible underlying molecular mechanisms. 2. Liver fibrosis was induced by carbon tetrachloride (CCl(4)) in BALB/c mice. Pirfenidone (250 mg/kg) and silymarin (50 mg/kg) were given to different groups of rats by gastric gavage for 4 weeks. Pirfenidone significantly attenuated fibrosis severity, as determined by histopathological scores and hydroxyproline levels in liver tissue, by 49.8 and 44.9%, respectively, compared with the CCl(4)-treated group. The antifibrotic effects of PFD were significantly greater than those of silymarin, as indicated by a decrease of 23.5 and 24.8% in histopathological scores and hydroxyproline levels, respectively. 3. Liver fibrosis was also induced by albumin antigen-antibody complex in Wistar rats, which were then treated with the same doses of PFD and silymarin for 8 weeks. Pirfenidone significantly reduced the degree of fibrosis compared with CCl(4)-treated rats (by 45.0 and 51.0% as determined by histopathological scores and hydroxyproline levels in liver tissue, respectively). The antifibrotic effects of PFD were comparable to those of silymarin. 4. The effects of PFD on the expression of extracellular matrix-associated genes in human hepatic stellate cells (the LX-2 cell line) were measured by real-time quantitative polymerase chain reaction. LX-2 cells were treated with or without 100 micromol/L or 1 mmol/L PFD for 24 h. Pirfenidone significantly inhibited the expression of a-smooth muscle actin and Type I collagen in 8 ng/mL transforming growth factor-beta1- or 5% fetal bovine serum-activated LX-2 cells in a dose-dependent manner. 5. In conclusion, the results of the present study demonstrate that PFD is effective in ameliorating fibrogenesis induced by CCl(4) in mice and by the albumin complex in rats. These effects were mediated mainly via inhibition of the activation of hepatic stellate cells, as well as antifibrotic actions (i.e. inhibition of collagen synthesis) of PFD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19413596     DOI: 10.1111/j.1440-1681.2009.05194.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  16 in total

1.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.

Authors:  Na Sun; Isis E Fernandez; Mian Wei; Yin Wu; Michaela Aichler; Oliver Eickelberg; Axel Walch
Journal:  Histochem Cell Biol       Date:  2015-12-08       Impact factor: 4.304

3.  The multifaceted role of pirfenidone and its novel targets.

Authors:  José Macías-Barragán; Ana Sandoval-Rodríguez; Jose Navarro-Partida; Juan Armendáriz-Borunda
Journal:  Fibrogenesis Tissue Repair       Date:  2010-09-01

Review 4.  Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Authors:  Pei-Suen Tsou; Andrew J Haak; Dinesh Khanna; Richard R Neubig
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

5.  Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth.

Authors:  Melanie Mediavilla-Varela; Kimberly Luddy; David Noyes; Farah K Khalil; Anthony M Neuger; Hatem Soliman; Scott J Antonia
Journal:  Cancer Biol Ther       Date:  2013-07-17       Impact factor: 4.742

6.  Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.

Authors:  Jacob D Estes; Cavan Reilly; Charles M Trubey; Courtney V Fletcher; Theodore J Cory; Michael Piatak; Samuel Russ; Jodi Anderson; Thomas G Reimann; Robert Star; Anthony Smith; Russell P Tracy; Anna Berglund; Thomas Schmidt; Vicky Coalter; Elena Chertova; Jeremy Smedley; Ashley T Haase; Jeffrey D Lifson; Timothy W Schacker
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

Review 7.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

8.  Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Authors:  Rebeca Escutia-Gutiérrez; J Samael Rodríguez-Sanabria; C Alejandra Monraz-Méndez; Jesús García-Bañuelos; Arturo Santos-García; Ana Sandoval-Rodríguez; Juan Armendáriz-Borunda
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

9.  Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis.

Authors:  Naglaa M El-Lakkany; Olfat A Hammam; Walaa H El-Maadawy; Afkar A Badawy; Afaf A Ain-Shoka; Fatma A Ebeid
Journal:  Parasit Vectors       Date:  2012-01-11       Impact factor: 3.876

10.  Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation.

Authors:  Hui Meng; Yong Xu
Journal:  Drug Des Devel Ther       Date:  2015-06-30       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.